Nevertheless, HDAC inhibitors, such as SAHA and Romidepsin, which have been approved for CTCL treatment, hold potential in the treatment of HNSCC. This evidence concerns the gene HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma.